35Pharma is a Montreal-based biopharmaceutical company developing ligand traps that target Activin and GDF biology. Its lead program, HS235, is being developed for pulmonary hypertension and cardiometabolic disease, with additional focus areas in heart failure and obesity. The company positions its platform around multi-specific, protein-engineered biologics designed for high unmet-need indications.